Combined use of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) as target therapy in non-small cell lung cancer (NSCLC)

Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja, Charles L. Vogel, Rachel A. Borson, Steven Limentani, Elizabeth Tan-Chiu, Ian E. Krop, Richard A. Michaelson, Sandhya Girish, Lukas Amler, Maoxia Zheng, Yu-Waye Chu, Barbara Klencke, Joyce A. O'Shaughnessy, Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy Journal of Clinical Oncology. ,vol. 29, pp. 398- 405 ,(2011) , 10.1200/JCO.2010.29.5865

Ji Luo, Brendan D Manning, Lewis C Cantley, Targeting the PI3K-Akt pathway in human cancer: Rationale and promise Cancer Cell. ,vol. 4, pp. 257- 262 ,(2003) , 10.1016/S1535-6108(03)00248-4

Steven J. Isakoff, José Baselga, Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Journal of Clinical Oncology. ,vol. 29, pp. 351- 354 ,(2011) , 10.1200/JCO.2010.31.6679

Daniele Cretella, Francesca Saccani, Federico Quaini, Caterina Frati, Costanza Lagrasta, Mara Bonelli, Cristina Caffarra, Andrea Cavazzoni, Claudia Fumarola, Maricla Galetti, Silvia La Monica, Luca Ampollini, Marcello Tiseo, Andrea Ardizzoni, Pier Petronini, Roberta R Alfieri, Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance Molecular Cancer. ,vol. 13, pp. 143- 143 ,(2014) , 10.1186/1476-4598-13-143

William Pao, Theresa Y Wang, Gregory J Riely, Vincent A Miller, Qiulu Pan, Marc Ladanyi, Maureen F Zakowski, Robert T Heelan, Mark G Kris, Harold E Varmus, KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib PLOS Medicine. ,vol. 2, ,(2005) , 10.1371/JOURNAL.PMED.0020017

M. A. Olayioye, The ErbB signaling network: receptor heterodimerization in development and cancer The EMBO Journal. ,vol. 19, pp. 3159- 3167 ,(2000) , 10.1093/EMBOJ/19.13.3159

Sandhya Girish, Manish Gupta, Bei Wang, Dan Lu, Ian E. Krop, Charles L. Vogel, Howard A. Burris III, Patricia M. LoRusso, Joo-Hee Yi, Ola Saad, Barbara Tong, Yu-Waye Chu, Scott Holden, Amita Joshi, Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemotherapy and Pharmacology. ,vol. 69, pp. 1229- 1240 ,(2012) , 10.1007/S00280-011-1817-3

Eric L. Sievers, Peter D. Senter, Antibody-Drug Conjugates in Cancer Therapy Annual Review of Medicine. ,vol. 64, pp. 15- 29 ,(2013) , 10.1146/ANNUREV-MED-050311-201823

Linda K. Ernst, Diana Metes, Ronald B. Herberman, Penelope A. Morel, Allelic polymorphisms in the FcγRIIC gene can influence its function on normal human natural killer cells Journal of Molecular Medicine. ,vol. 80, pp. 248- 257 ,(2002) , 10.1007/S00109-001-0294-2

Raphael A. Clynes, Terri L. Towers, Leonard G. Presta, Jeffrey V. Ravetch, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nature Medicine. ,vol. 6, pp. 443- 446 ,(2000) , 10.1038/74704